Nicergoline, a semi-synthetic ergoline, which is licensed in some regions of the EU as a treatment for cognitive impairment, appears to reduce the symptoms of central vertigo and improve quality of life in adult and elderly patients, according to the results of a study published in the November issue of Clinical Drug Investigation (2002; 22:731-740).
Researchers assessed the outcomes of 89 adult and elderly patients with central balance disorders who were randomised to receive nicergoline 30 mg or placebo twice daily for 3 months. At the end of the study period they noted that patients treated with nicergoline experienced significantly greater improvements in dizziness scores than those who received placebo.
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!